TikoMed's ILB® mobilizes and modulates key growth factors that trigger a cascade of neuroprotective mechanisms able to target all neuroinflammation-driven diseases including ALS

Corporate Breaking News

Home : TikoMed's ILB® mobilizes and modulates key growth factors that trigger a cascade of neuroprotective mechanisms able to target all neuroinflammation-driven diseases including ALS

Aug 31 2022	TikoMed's ILB® mobilizes and modulates key growth factors that trigger a cascade of neuroprotective mechanisms able to target all neuroinflammation-driven diseases including ALS
VIKEN, Sweden, Aug. 31, 2022 /PRNewswire/ -- TikoMed, a biopharmaceutical company focused on harnessing the medical potential of the body's ability to self-repair and regenerate, today announced the publication in Frontiers in Phamacology of peer-reviewed research supporting the unique...


Source:https://www.prnewswire.com:443/news-releases/tikomeds-ilb-mobilizes-and-modulates-key-growth-factors-that-trigger-a-cascade-of-neuroprotective-mechanisms-able-to-target-all-neuroinflammation-driven-diseases-including-als-301615277.html

Related News
» Online Jewelry Market to Record a 14.97% Y-O-Y Growth Rate in 2022, Increase in the Adoption of an Omnichannel Strategy to be a Major Trend - Technavio » HoverTouch™: First AI and Computer Vision Solution launched by Spacee that Transforms Existing Retail Surfaces Into Interactive Customer Experiences